Page updated ·next FDA decision on the calendar·Data as of Nov 5, 2026 9:00 PM ET
Price into the decision (T-120)
Daily close, T-120 (8/15/24) through T+5. Run-up high $105.14 on 1/29/25, low $80.05 on 1/13/25 (T-120 to T-1). FDA decision 1/30/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 16, 2025, 14 days before the decision date, at-the-money options priced a move of ±12.2% through Feb 21, 2025 (the first listed expiry after the decision; ATM implied volatility 49%). The stock closed +3.5% at the first close across the decision and +8.4% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.
Questions
Was SYMBRAVO (meloxicam and rizatriptan) approved by the FDA?
Yes. The FDA approved the application for SYMBRAVO (meloxicam and rizatriptan) on January 30, 2025, per the FDA's own record. The primary source is linked on this page.
What was SYMBRAVO (meloxicam and rizatriptan) under FDA review for?
The application covered Migraine. The FDA approved the application on January 30, 2025.
How did AXSM stock react to the FDA decision?
On the decision day AXSM moved +3.5%. That is the recorded reaction to this specific event. Historical measurement, not a prediction, and not investment advice.